Dupilumab
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Dupilumab (Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. Dupilumab is in Phase III development for both asthma and atopic dermatitis.
Analyst Outlook
While dupilumab (Regeneron/Sanofi) has demonstrated positive efficacy in its Phase IIb study and acts via a novel mechanism of action, inhibiting signaling of interleukin (IL)-4 and IL-13, there are limited data currently available and the drug’s potential in asthma is not yet clear. Furthermore, dupilumab’s development for asthma lags behind several other biologics, with its pivotal Phase III Liberty Asthma Quest study initiated in April 2015. With limited data currently available, Datamonitor Healthcare does not provide a forecast for dupilumab in asthma at this time.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 dupilumab : Asthma
10 dupilumab : Atopic dermatitis
LIST OF FIGURES
6 Figure 1: Dupilumab for asthma – SWOT analysis
7 Figure 2: Datamonitor Healthcare’s drug assessment summary of dupilumab in asthma
8 Figure 3: Datamonitor Healthcare’s drug assessment summary of dupilumab in asthma
15 Figure 4: Dupilumab for atopic dermatitis – SWOT analysis
16 Figure 5: Datamonitor Healthcare’s drug assessment summary of dupilumab in atopic
dermatitis
16 Figure 6: Datamonitor Healthcare’s drug assessment summary of dupilumab in atopic
dermatitis
LIST OF TABLES
4 Table 1: Dupilumab drug profile
5 Table 2: Dupilumab Phase III trials in asthma
10 Table 3: Dupilumab drug profile
13 Table 4: Dupilumab Phase III trials in atopic dermatitis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Gene Editing: The Next Breakthrough in Regenerative Medicine 
Sign up to the